T. Rowe Price Associates
CPRX

T. Rowe Price Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

T. Rowe Price Associates’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.2M Buy
773,446
+24,665
+3% +$588K ﹤0.01% 1051
2025
Q4 		$17.5M Buy
748,781
+5,106
+0.7% +$114K ﹤0.01% 1088
2025
Q3 		$14.7M Buy
743,675
+7,977
+1% +$164K ﹤0.01% 1135
2025
Q2 		$16M Sell
735,698
-241,925
-25% -$5.71M ﹤0.01% 1005
2025
Q1 		$23.7M Sell
977,623
-237,815
-20% -$5.36M ﹤0.01% 914
2024
Q4 		$25.4M Sell
1,215,438
-18,945
-2% -$407K ﹤0.01% 936
2024
Q3 		$24.5M Buy
1,234,383
+1,531
+0.1% +$28.4K ﹤0.01% 953
2024
Q2 		$19.1M Buy
1,232,852
+13,434
+1% +$209K ﹤0.01% 972
2024
Q1 		$19.4M Buy
1,219,418
+22,860
+2% +$344K ﹤0.01% 983
2023
Q4 		$20.1M Buy
1,196,558
+18,390
+2% +$251K ﹤0.01% 957
2023
Q3 		$13.8M Buy
1,178,168
+76,778
+7% +$1.03M ﹤0.01% 1007
2023
Q2 		$14.8M Buy
1,101,390
+71,711
+7% +$1.03M ﹤0.01% 1011
2023
Q1 		$17.1M Buy
1,029,679
+78,905
+8% +$1.3M ﹤0.01% 956
2022
Q4 		$17.7M Buy
950,774
+935,316
+6,051% +$14.4M ﹤0.01% 942
2022
Q3 		$199K Buy
+15,458
New +$183K ﹤0.01% 2546

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

T. Rowe Price Associates's CPRX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Catalyst Pharmaceutical (CPRX) stake by 3.3% in Q1 2026, buying an estimated $588K and bringing the position to 773,446 shares worth $19.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

T. Rowe Price Associates first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $25.4M in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • T. Rowe Price Associates held 773,446 shares of Catalyst Pharmaceutical worth $19.2M as of Q1 2026.
  • T. Rowe Price Associates bought 24,665 Catalyst Pharmaceutical shares in Q1 2026, an estimated $588K.
  • Catalyst Pharmaceutical made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1051 holding.
  • T. Rowe Price Associates first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
  • T. Rowe Price Associates's Catalyst Pharmaceutical position peaked at $25.4M in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.